Read by QxMD icon Read

Testosterone and breast cancer risk and menopause

Beata Krusinska, Lidia Wadolowska, Malgorzata Anna Slowinska, Maciej Biernacki, Marek Drozdowski, Tomasz Chadzynski
Breast cancer is the most diagnosed cancer in women worldwide. Studies regarding complex breast cancer aetiology are limited and the results are inconclusive. We investigated the associations between dietary patterns (DPs), metabolic-hormone profiles (M-HPs), and breast cancer risk. This case-control study involved 420 women aged 40⁻79 years from north-eastern Poland, including 190 newly-diagnosed breast cancer cases. The serum concentration of lipid components, glucose, and hormones (oestradiol, progesterone, testosterone, prolactin, cortisol, insulin) was marked in 129 post-menopausal women (82 controls, 47 cases)...
December 19, 2018: Nutrients
Ritika Gera, Salim Tayeh, Hiba El-Hage Chehade, Kefah Mokbel
BACKGROUND/AIM: Hypoactive sexual desire disorder (HSDD) is hypothesised to manifest in postmenopausal women at onset of menopause due to decreased oestrogen levels. Transdermal testosterone is a potential treatment option. This systematic review explores the relationship between the incidence of breast cancer and transdermal testosterone use. MATERIALS AND METHODS: Searches were conducted on the PubMed and Ovid databases. In Ovid, the advanced search function was used: 'transdermal testosterone not male'...
December 2018: Anticancer Research
Xuehong Zhang, Megan Rice, Shelley S Tworoger, Bernard A Rosner, A Heather Eliassen, Rulla M Tamimi, Amit D Joshi, Sara Lindstrom, Jing Qian, Graham A Colditz, Walter C Willett, Peter Kraft, Susan E Hankinson
BACKGROUND: No prior study to our knowledge has examined the joint contribution of a polygenic risk score (PRS), mammographic density (MD), and postmenopausal endogenous hormone levels-all well-confirmed risk factors for invasive breast cancer-to existing breast cancer risk prediction models. METHODS AND FINDINGS: We conducted a nested case-control study within the prospective Nurses' Health Study and Nurses' Health Study II including 4,006 cases and 7,874 controls ages 34-70 years up to 1 June 2010...
September 2018: PLoS Medicine
N Brusselaers, R M Tamimi, P Konings, B Rosner, H-O Adami, J Lagergren
Background: There are considerable knowledge gaps concerning different estrogen and progestin formulations, regimens, and modes of administration of menopausal hormone therapy (HT) and the risk of breast cancer. Our objective was to assess the different treatment options for menopausal HT and the risk of breast cancer. Patients and methods: This Swedish prospective nationwide cohort study included all women who received ≥1 HT prescription during the study period 2005-2012 (290 186 ever-users), group-level matched (1 : 3) to 870 165 never-users; respectively, 6376 (2...
August 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Kavitha Ganesan, Yacob Habboush, Senan Sultan
Female hypoactive sexual desire disorder (HSDD) is a multifactorial sexual dysfunction disorder characterized by a decrease in sexual desire and personal distress. HSDD occurs in naturally occurring postmenopausal women or secondary to oophorectomy. Multiple studies have assessed the use of transdermal testosterone (TDT) as a management option for patients with HSDD. Our aim is to assess published studies using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework for the quality of evidence regarding testosterone use as a short- and long-term therapy for HSDD...
March 31, 2018: Curēus
Giorgio Secreto, Paola Muti, Milena Sant, Elisabetta Meneghini, Vittorio Krogh
Five years of adjuvant therapy with anti-estrogens reduce the incidence of disease progression by about 50% in estrogen receptor-positive breast cancer patients, but late relapse can still occur after anti-estrogens have been discontinued. In these patients, excessive androgen production may account for renewed excessive estrogen formation and increased risks of late relapse. In the 50% of patients who do not benefit with anti-estrogens, the effect of therapy is limited by de novo or acquired resistance to treatment...
November 2017: Endocrine-related Cancer
Xiaoxue Xing, Lina Su, Patrick Fordjour Asare, Lingyan Wang, Lan Li, Erwei Liu, Bing Yu, Yan Zhu, Xiumei Gao, Guanwei Fan
What is the central question of this study? Does Danzhi Qing'e (DZQE) regulate lipid metabolism and improve ovarian function in a rat model of perimenopausal hyperlipidaemia, and could this effect be mediated through the AMPK pathway? What is the main finding and its importance? We revealed that DZQE is a pharmacotherapy that could activate the AMPK pathway to improve ovarian function and lipid metabolism during perimenopause complicated with hyperlipidaemia syndrome in an animal model. Thus, this study provides a novel therapeutic option for treating perimenopausal syndrome and highlights the therapeutic potential of DZQE in perimenopausal rats...
November 1, 2016: Experimental Physiology
A Heather Eliassen, Anne Zeleniuch-Jacquotte, Bernard Rosner, Susan E Hankinson
BACKGROUND: Anti-Müllerian hormone (AMH) is a member of the TGFβ family of growth and differentiation factors with a key role in regulating folliculogenesis. In experimental studies, using supraphysiologic concentrations, AMH inhibits breast cancer growth. However, high levels of AMH were associated with increased breast cancer risk in two prior prospective epidemiologic studies. METHODS: We conducted a nested case-control study of premenopausal plasma AMH and breast cancer risk within the Nurses' Health Study (NHS) and NHSII...
May 2016: Cancer Epidemiology, Biomarkers & Prevention
Robert T Chatterton, Richard E Heinz, Angela J Fought, David Ivancic, Claire Shappell, Subhashini Allu, Susan Gapstur, Denise M Scholtens, Peter H Gann, Seema A Khan
Prior reports identify higher serum concentrations of estrogens and androgens as risk factors for breast cancer, but steroids in nipple aspirate fluid (NAF) may be more related to risk. Incident breast cancer cases and mammography controls were recruited. Sex steroids were measured in NAF from the unaffected breasts of cases and one breast of controls. Menopausal status and menstrual cycle phase were determined. NAF steroids were purified by HPLC and quantified by immunoassays. Conditional logistic regression models were used to examine associations between NAF hormones and case-control status...
April 2016: Hormones & Cancer
Paige E Tucker, Max K Bulsara, Stuart G Salfinger, Jason Jit-Sun Tan, Helena Green, Paul A Cohen
OBJECTIVES: To determine the prevalence of sexual dysfunction in women after risk-reducing salpingo-oophorectomy (RRSO) and to assess factors which may influence sexual wellbeing following this procedure. METHODS: This work is a cross-sectional study of women who underwent RRSO at a tertiary gynecologic oncology unit between January 2009 and October 2014. Data collection involved a comprehensive questionnaire including validated measures of sexual function, sexual distress, relationship satisfaction, body image, impact of event, menopause specific quality of life, and general quality of life...
January 2016: Gynecologic Oncology
Kaoutar Ennour-Idrissi, Elizabeth Maunsell, Caroline Diorio
INTRODUCTION: Exposure to high levels of endogenous estrogens is a main risk factor for breast cancer in women, and in observational studies was found to be inversely associated with physical activity. The objective of the present study is to determine the effect of physical activity interventions on sex hormone levels in healthy women. METHODS: Electronic databases (MEDLINE, EMBASE, CENTRAL), from inception to December 2014, and reference lists of relevant reviews and clinical trials were searched, with no language restrictions applied...
November 5, 2015: Breast Cancer Research: BCR
Susan R Davis, Sarah Wahlin-Jacobsen
Testosterone is an essential hormone for women, with physiological actions mediated directly or via aromatisation to oestradiol throughout the body. Despite the crucial role of testosterone and the high circulating concentrations of this hormone relative to oestradiol in women, studies of its action and the effects of testosterone deficiency and replacement in women are scarce. The primary indication for the prescription of testosterone for women is loss of sexual desire, which causes affected women substantial concern...
December 2015: Lancet Diabetes & Endocrinology
Brian Hutton, Fatemeh Yazdi, Louise Bordeleau, Scott Morgan, Chris Cameron, Salmaan Kanji, Dean Fergusson, Andrea Tricco, Sharon Straus, Becky Skidmore, Mona Hersi, Misty Pratt, Sasha Mazzarello, Melissa Brouwers, David Moher, Mark Clemons
BACKGROUND: Breast and prostate cancers are the most commonly diagnosed non-dermatologic malignancies in Canada. Agents including endocrine therapies (e.g., aromatase inhibitors, gonadotrophin-releasing hormone analogs, anti-androgens, tamoxifen) and chemotherapy have improved survival for both conditions. As endocrine manipulation is a mainstay of treatment, it is not surprising that hot flashes are a common and troublesome adverse effect. Hot flashes can cause chills, night sweats, anxiety, and insomnia, lessening patients' quality of life...
August 27, 2015: Systematic Reviews
S Rice, L Pellat, A Ahmetaga, G Bano, H D Mason, S A Whitehead
Evidence has been accumulating for a role for metformin in reducing breast cancer risk in post-menopausal women. It inhibits growth of breast cancer cells via several mechanisms, primarily the AMPK/mTOR signalling pathway. Another possible protective mechanism may be the ability of metformin to inhibit aromatase activity. In the present study, we investigated the effects of metformin on the basal growth of MCF-7 cells, after oestradiol (E2) stimulation and after the inhibition of mTOR by rapamycin. Secondly, we investigated the effects of metformin on the activity of a number of steroidogenic enzymes and the mRNA expression of aromatase and steroid sulphatase (STS)...
April 2015: International Journal of Molecular Medicine
Ulla Arthur Hvidtfeldt, Anne Tjønneland, Niels Keiding, Theis Lange, Ingelise Andersen, Thorkild I A Sørensen, Eva Prescott, Åse Marie Hansen, Morten Grønbæk, Stig Egil Bojesen, Finn Diderichsen, Naja Hulvej Rod
BACKGROUND: Alcohol consumption, increased body mass index (BMI), and hormone therapy are risk factors for postmenopausal breast cancer, but their combined effects are not well understood. Because hormone therapy is effective for the relief of menopausal symptoms, the identification of "high-risk" users is important for therapeutic reasons. We investigated interactions between hormone therapy use and alcohol-use/high BMI status in relation to invasive breast cancer risk, both overall and according to estrogen receptor (ER) status...
May 2015: Epidemiology
Frank Z Stanczyk, Brett W Mathews, Mark E Sherman
A systematic review of the literature on sex steroid measurement in breast tissue identified only 19 articles meeting the following criteria: menopausal status given; steroids measured in tissue homogenates by conventional RIA with a purification step or by mass spectrometry; and values reported per g tissue or per g protein. Twelve articles were analyzed in detail for: ratios of sex steroid hormone levels in cancerous or benign tissues to blood levels, stratified by menopausal status; ratios between the different hormone levels within tissues or within blood; and difference in these ratios between tissue and blood compartments...
July 2015: Steroids
Joanne Kotsopoulos, Amy L Shafrir, Megan Rice, Susan E Hankinson, A Heather Eliassen, Shelley S Tworoger, Steven A Narod
Oophorectomy prior to natural menopause reduces breast cancer risk. We evaluated whether timing of oophorectomy (during premenopause vs. postmenopause) or hysterectomy was associated with hormone levels, specifically estradiol, estrone, estrone sulfate, testosterone, sex hormone binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), and prolactin, using data from the Nurses' Health Study. We included 2,251 postmenopausal women not using hormones who provided blood samples in 1989-1990 and/or 2000-2002, and who were controls in various nested case-control studies...
February 2015: Hormones & Cancer
Zeina G Khodr, Mark E Sherman, Ruth M Pfeiffer, Gretchen L Gierach, Louise A Brinton, Roni T Falk, Deesha A Patel, Laura M Linville, Daphne Papathomas, Susan E Clare, Daniel W Visscher, Carolyn Mies, Stephen M Hewitt, Anna Maria V Storniolo, Adrian Rosebrock, Jesus J Caban, Jonine D Figueroa
BACKGROUND: Terminal duct lobular units (TDLU) are the predominant source of breast cancers. Lesser degrees of age-related TDLU involution have been associated with increased breast cancer risk, but factors that influence involution are largely unknown. We assessed whether circulating hormones, implicated in breast cancer risk, are associated with levels of TDLU involution using data from the Susan G. Komen Tissue Bank (KTB) at the Indiana University Simon Cancer Center (2009-2011). METHODS: We evaluated three highly reproducible measures of TDLU involution, using normal breast tissue samples from the KTB (n = 390): TDLU counts, median TDLU span, and median acini counts per TDLU...
December 2014: Cancer Epidemiology, Biomarkers & Prevention
Arlette C Perry, Lorena Martin
A sexual dimorphism exists in which increased abdominal and visceral adipose tissue (VAT) - found in women and marked by low sex hormone binding globulin (SHBG) and high bioavailable testosterone (BT) - is related to the metabolic risk profile. In men, increased BT is related to decreased abdominal obesity and a decrease in the metabolic risk profile. In women, race differences have been found in androgenic sex steroids including SHBG and BT as well as central fat distribution, creating inherently greater metabolic risk for certain populations...
September 2014: Hormone Molecular Biology and Clinical Investigation
Geoffrey C Kabat, Victor Kamensky, Moonseong Heo, Jennifer W Bea, Lifang Hou, Dorothy S Lane, Simin Liu, LiHong Qi, Michael S Simon, Jean Wactawski-Wende, Thomas E Rohan
OBJECTIVES: Testosterone supplementation is being prescribed increasingly to treat symptoms of hormone deficiency in pre- and postmenopausal women; however, studies of the association of testosterone therapy, alone or in combination with estrogen, with risk of breast cancer are limited. The current study assessed the association of combination conjugated esterified estrogen and methyltestosterone (CEE+MT) use and breast cancer risk in postmenopausal women in the Women's Health Initiative (WHI)...
September 2014: Maturitas
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"